The long-serving chief executive of blood products and vaccine supplier CSL will take home $4.9 million in one-off payments when he severs ties with the company in October.
Brian McNamee could also be awarded shares worth about $18 million in coming years under long-term incentive plans.
Dr McNamee's 23-year career as chief executive of CSL ended on Friday, and his contract with the company expires on October 15.
Under his leadership, CSL has grown from a small government enterprise to a listed company worth more than $30 billion.
Dr McNamee will be paid a $2.8 million severance payment as well as $2.1 million for nearly 200 days of untaken annual leave and sick leave.
He is also entitled to almost 125,500 performance rights and more than 179,000 performance options as part of long-term incentives, worth about $18 million.